Tags

Type your tag names separated by a space and hit enter

Zoledronic acid: a review of its use in the treatment of osteoporosis.
Drugs Aging. 2008; 25(11):963-86.DA

Abstract

Zoledronic acid (Aclasta; Reclast), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. Intravenous zoledronic acid 5 mg once yearly is effective in reducing the risk of several types of fracture in patients with postmenopausal osteoporosis or recent low-trauma hip fracture. Moreover, improvements in bone mineral density (BMD) and reductions in markers of bone turnover are also generally observed. Zoledronic acid is generally well tolerated. Additional comparative data are required to definitively position zoledronic acid with respect to other agents. In the meantime, intravenous zoledronic acid 5 mg once yearly is a convenient and effective treatment option that may have an advantage over some other agents, for which adherence to treatment regimens is a recognized problem.

Authors+Show Affiliations

Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nzNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18947264

Citation

Deeks, Emma D., and Caroline M. Perry. "Zoledronic Acid: a Review of Its Use in the Treatment of Osteoporosis." Drugs & Aging, vol. 25, no. 11, 2008, pp. 963-86.
Deeks ED, Perry CM. Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs Aging. 2008;25(11):963-86.
Deeks, E. D., & Perry, C. M. (2008). Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs & Aging, 25(11), 963-86. https://doi.org/10.2165/0002512-200825110-00007
Deeks ED, Perry CM. Zoledronic Acid: a Review of Its Use in the Treatment of Osteoporosis. Drugs Aging. 2008;25(11):963-86. PubMed PMID: 18947264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Zoledronic acid: a review of its use in the treatment of osteoporosis. AU - Deeks,Emma D, AU - Perry,Caroline M, PY - 2008/10/25/pubmed PY - 2009/1/24/medline PY - 2008/10/25/entrez SP - 963 EP - 86 JF - Drugs & aging JO - Drugs Aging VL - 25 IS - 11 N2 - Zoledronic acid (Aclasta; Reclast), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. Intravenous zoledronic acid 5 mg once yearly is effective in reducing the risk of several types of fracture in patients with postmenopausal osteoporosis or recent low-trauma hip fracture. Moreover, improvements in bone mineral density (BMD) and reductions in markers of bone turnover are also generally observed. Zoledronic acid is generally well tolerated. Additional comparative data are required to definitively position zoledronic acid with respect to other agents. In the meantime, intravenous zoledronic acid 5 mg once yearly is a convenient and effective treatment option that may have an advantage over some other agents, for which adherence to treatment regimens is a recognized problem. SN - 1170-229X UR - https://www.unboundmedicine.com/medline/citation/18947264/Zoledronic_acid:_a_review_of_its_use_in_the_treatment_of_osteoporosis_ L2 - https://dx.doi.org/10.2165/0002512-200825110-00007 DB - PRIME DP - Unbound Medicine ER -